Shoichiro Horita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shoichiro Horita has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Kenju Shimomura
Department of Bioregulation and Pharmacological Medicine, Fukushima Medical University School of Medicine
7 shared publications - Yuko Maejima
Department of Bioregulation and Pharmacological Medicine Fukushima Medical University School of Medicine Fukushima Japan
5 shared publications - Shingen Misaka
Department of Bioregulation and Pharmacological Medicine Fukushima Medical University School of Medicine Fukushima Japan
4 shared publications Yuko Maejima
Department of Bioregulation and Pharmacological Medicine Fukushima Medical University School of Medicine Fukushima Japan
4 shared publicationsGuy Watanabe
Department of Nephrology and Hypertension Fukushima Medical University School of Medicine Fukushima Japan
3 shared publicationsJunichiro James Kazama
Department of Nephrology and Hypertension Fukushima Medical University School of Medicine Fukushima Japan
3 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by Wiley in Physiological Reports
- Vol. 13 (15) , e70481
Kir6.2 channel activity is regulated by interaction of transmembrane domains 1 and 2 through I167 in the bundle‐crossing gate
ATP‐sensitive potassium (KATP) channel in pancreatic β‐cells is composed of four pore‐forming inward rectifier potassium (Kir) 6.2 subunits and four regulatory sulfonylurea receptor (SUR) 1 subunits and regulate insulin secretion. Kir6.2 consists of a N‐terminal region, an outer transmembrane helix (TM1), an intramembrane region that functions as a potassium selectivity filter, an inner transmembrane helix (TM2) that forms a bundle‐crossing gate, and a C‐terminal cytoplasmic domain. Mutations in the Kir6.2 subunit can cause neonatal diabetes with severe neurological features (DEND syndrome). The DEND syndrome‐inducing I167L mutation of Kir6.2 increases the open probability (Po) of the KATP channel. To investigate the gating mechanism impacted by this mutation in Kir6.2 alone, we used C‐terminus‐truncated Kir6.2 channels to ascertain the impact of I167 mutations on Po in Kir6.2 channels in the absence of SUR1. We found that I167L and I167F mutations showed an increased Po while the Po of other mutations (I167A, I167V) were unchanged when compared to wild‐type channels. By mutating residues in TM1 (W68, L72, F75) that may interact with I167, we found that a double mutation of I167L and F75A normalized the Po. These results would suggest that I167 may play an important role in stabilizing the open state of Kir6.2 channels.
- 1 August 2025
- Published by Wiley in Physiological Reports
- Vol. 13 (15) , e70481
Open AccessKir6.2 channel activity is regulated by interaction of transmembrane domains 1 and 2 through I167 in the bundle‐crossing gate
ATP‐sensitive potassium (KATP) channel in pancreatic β‐cells is composed of four pore‐forming inward rectifier potassium (Kir) 6.2 subunits and four regulatory sulfonylurea receptor (SUR) 1 subunits and regulate insulin secretion. Kir6.2 consists of a N‐terminal region, an outer transmembrane helix (TM1), an intramembrane region that functions as a potassium selectivity filter, an inner transmembrane helix (TM2) that forms a bundle‐crossing gate, and a C‐terminal cytoplasmic domain. Mutations in the Kir6.2 subunit can cause neonatal diabetes with severe neurological features (DEND syndrome). The DEND syndrome‐inducing I167L mutation of Kir6.2 increases the open probability (Po) of the KATP channel. To investigate the gating mechanism impacted by this mutation in Kir6.2 alone, we used C‐terminus‐truncated Kir6.2 channels to ascertain the impact of I167 mutations on Po in Kir6.2 channels in the absence of SUR1. We found that I167L and I167F mutations showed an increased Po while the Po of other mutations (I167A, I167V) were unchanged when compared to wild‐type channels. By mutating residues in TM1 (W68, L72, F75) that may interact with I167, we found that a double mutation of I167L and F75A normalized the Po. These results would suggest that I167 may play an important role in stabilizing the open state of Kir6.2 channels.
- Open Access
- 13 April 2025
- Published by Wiley in Physiological Reports
- Vol. 13 (7) , e70320
Canagliflozin‐induced renal glutathione distribution mapping in non‐diabetic male rat kidneys
Canagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, has direct renoprotective effects beyond lowering blood glucose levels. The inhibition of sodium reabsorption via SGLT2 reduces the overload on proximal tubules, thereby suppressing the generation of reactive oxygen species (ROS) and preventing a decline in renal function. To clarify the pharmacological mechanism of SGLT2 inhibitor, we investigated the effects of canagliflozin on oxidative stress in the kidneys of normal, non‐diabetic Sprague–Dawley rats. Screening using mass spectrometry images revealed a significant elevation map of the reduced form of glutathione in the renal cortex of canagliflozin‐treated non‐diabetic rats. These results suggest that canagliflozin reduces oxidative stress through ROS scavenging mechanisms. Considering that ROS play major roles in renal dysfunction regardless of diabetes mellitus, these findings suggest that canagliflozin is applicable to a broader range of renal diseases beyond diabetes.
- 13 April 2025
- Published by Wiley in Physiological Reports
- Vol. 13 (7) , e70320
Open AccessCanagliflozin‐induced renal glutathione distribution mapping in non‐diabetic male rat kidneys
Canagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, has direct renoprotective effects beyond lowering blood glucose levels. The inhibition of sodium reabsorption via SGLT2 reduces the overload on proximal tubules, thereby suppressing the generation of reactive oxygen species (ROS) and preventing a decline in renal function. To clarify the pharmacological mechanism of SGLT2 inhibitor, we investigated the effects of canagliflozin on oxidative stress in the kidneys of normal, non‐diabetic Sprague–Dawley rats. Screening using mass spectrometry images revealed a significant elevation map of the reduced form of glutathione in the renal cortex of canagliflozin‐treated non‐diabetic rats. These results suggest that canagliflozin reduces oxidative stress through ROS scavenging mechanisms. Considering that ROS play major roles in renal dysfunction regardless of diabetes mellitus, these findings suggest that canagliflozin is applicable to a broader range of renal diseases beyond diabetes.
- 1 October 2024
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 327 (4) , F581-F590
Peripheral dopamine suppression and elevated cystatin C in early diabetic nephropathy in spontaneously diabetic rats
By administering a peripheral decarboxylase inhibitor, we revealed that peripheral dopamine inhibits both the increase in urinary 8-iso-prostaglandin F2α, an oxidative stress marker, and the increase in plasma cystatin C, an early renal dysfunction marker, even in the early stages of diabetic nephropathy characterized by glomerular hyperfiltration. By visualizing renal dopamine precursor distribution, we highlighted the role of endogenous renal dopamine in oxidative stress and renal function following the onset of glomerular hyperfiltration.
- 1 October 2024
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 327 (4) , F581-F590
Peripheral dopamine suppression and elevated cystatin C in early diabetic nephropathy in spontaneously diabetic rats
By administering a peripheral decarboxylase inhibitor, we revealed that peripheral dopamine inhibits both the increase in urinary 8-iso-prostaglandin F2α, an oxidative stress marker, and the increase in plasma cystatin C, an early renal dysfunction marker, even in the early stages of diabetic nephropathy characterized by glomerular hyperfiltration. By visualizing renal dopamine precursor distribution, we highlighted the role of endogenous renal dopamine in oxidative stress and renal function following the onset of glomerular hyperfiltration.
- 7 November 2022
- Published by Springer Nature in EMBO Reports
- Vol. 24 (1) , e54042
ZBTB2 links p53 deficiency to HIF‐1‐mediated hypoxia signaling to promote cancer aggressiveness
Aberrant activation of the hypoxia-inducible transcription factor HIF-1 and dysfunction of the tumor suppressor p53 have been reported to induce malignant phenotypes and therapy resistance of cancers. However, their mechanistic and functional relationship remains largely unknown. Here, we reveal a mechanism by which p53 deficiency triggers the activation of HIF-1-dependent hypoxia signaling and identify zinc finger and BTB domain-containing protein 2 (ZBTB2) as an important mediator. ZBTB2 forms homodimers via its N-terminus region and increases the transactivation activity of HIF-1 only when functional p53 is absent. The ZBTB2 homodimer facilitates invasion, distant metastasis, and growth of p53-deficient, but not p53-proficient, cancers. The intratumoral expression levels of ZBTB2 are associated with poor prognosis in lung cancer patients. ZBTB2 N-terminus-mimetic polypeptides competitively inhibit ZBTB2 homodimerization and significantly suppress the ZBTB2-HIF-1 axis, leading to antitumor effects. Our data reveal an important link between aberrant activation of hypoxia signaling and loss of a tumor suppressor and provide a rationale for targeting a key mediator, ZBTB2, to suppress cancer aggressiveness.
- 7 November 2022
- Published by Springer Nature in EMBO Reports
- Vol. 24 (1) , e54042
ZBTB2 links p53 deficiency to HIF‐1‐mediated hypoxia signaling to promote cancer aggressiveness
Aberrant activation of the hypoxia-inducible transcription factor HIF-1 and dysfunction of the tumor suppressor p53 have been reported to induce malignant phenotypes and therapy resistance of cancers. However, their mechanistic and functional relationship remains largely unknown. Here, we reveal a mechanism by which p53 deficiency triggers the activation of HIF-1-dependent hypoxia signaling and identify zinc finger and BTB domain-containing protein 2 (ZBTB2) as an important mediator. ZBTB2 forms homodimers via its N-terminus region and increases the transactivation activity of HIF-1 only when functional p53 is absent. The ZBTB2 homodimer facilitates invasion, distant metastasis, and growth of p53-deficient, but not p53-proficient, cancers. The intratumoral expression levels of ZBTB2 are associated with poor prognosis in lung cancer patients. ZBTB2 N-terminus-mimetic polypeptides competitively inhibit ZBTB2 homodimerization and significantly suppress the ZBTB2-HIF-1 axis, leading to antitumor effects. Our data reveal an important link between aberrant activation of hypoxia signaling and loss of a tumor suppressor and provide a rationale for targeting a key mediator, ZBTB2, to suppress cancer aggressiveness.
- Open Access
- 16 August 2022
- Published by Springer Nature in Research Square
Activation of renal dopaminergic system in early diabetic nephropathy
Early diabetic nephropathy is typically diagnosed using the urinary albumin-to-creatinine ratio or creatinine clearance to detect renal function decline in diabetic patients. However, it is not yet fully understood how the alteration of the renal dopaminergic system occurs during early diabetic nephropathy progression, or whether the system is a predictor of renal function associated with diabetic nephropathy. Mass spectroscopy imaging of the kidneys of spontaneously diabetic torii rats, an animal model of diabetes with diabetic nephropathy, revealed clearly differing a dopamine precursor L-dihydroxyphenylalanine distributions. Furthermore, the significantly increased excretion of urinary L-dihydroxyphenylalanine-to-creatinine or urinary dopamine-to-creatinine ratios are observed before the development of microalbuminuria. The present study represents the renal dopaminergic system responses along the progression of diabetic nephropathy, and our results will facilitate understanding of the association between early diabetic nephropathy pathogenesis and the renal dopaminergic system.
- 16 August 2022
- Published by Springer Nature in Research Square
Open AccessActivation of renal dopaminergic system in early diabetic nephropathy
Early diabetic nephropathy is typically diagnosed using the urinary albumin-to-creatinine ratio or creatinine clearance to detect renal function decline in diabetic patients. However, it is not yet fully understood how the alteration of the renal dopaminergic system occurs during early diabetic nephropathy progression, or whether the system is a predictor of renal function associated with diabetic nephropathy. Mass spectroscopy imaging of the kidneys of spontaneously diabetic torii rats, an animal model of diabetes with diabetic nephropathy, revealed clearly differing a dopamine precursor L-dihydroxyphenylalanine distributions. Furthermore, the significantly increased excretion of urinary L-dihydroxyphenylalanine-to-creatinine or urinary dopamine-to-creatinine ratios are observed before the development of microalbuminuria. The present study represents the renal dopaminergic system responses along the progression of diabetic nephropathy, and our results will facilitate understanding of the association between early diabetic nephropathy pathogenesis and the renal dopaminergic system.
- Open Access
- 5 July 2021
- Published by MDPI AG in Applied Sciences
- Vol. 11 (13) , 6217
Comparative Analysis of Derivatization Reagents for Catecholamines and Amino Acids
We compared four derivatization reagents to analyze catecholamines and amino acids by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. 2,4,6-Trimethylpyrylium tetrafluoroborate (TMPy), 2,4-diphenyl-pyranylium tetrafluoroborate (DPP-TFB), 4-(anthracen-9-yl)-2-fluoro-1-methylpyridin-1-ium iodide (FMP-10), and triphenyl pyrilium (TPP) were used as derivatization reagents that can specifically modify primary amines or hydroxy groups in target molecules. Three derivatization reagents, not including TPP, reacted with all target molecules. The derived catecholamines dopamine and L-DOPA, and the amino acids GABA and glycine, were efficiently ionized in comparison with non-derivatized targets. Comparative analysis indicated that TMPy and FMP-10 produced general increases in signal-to-noise ratios (S/N), whereas DPP and TPP produced specific increases in the S/N of GABA and DA. Notably, TMPy is a small molecule that efficiently reacts with target molecules due to the absence of high bulk and steric hinderance.
- 5 July 2021
- Published by MDPI AG in Applied Sciences
- Vol. 11 (13) , 6217
Open AccessComparative Analysis of Derivatization Reagents for Catecholamines and Amino Acids
We compared four derivatization reagents to analyze catecholamines and amino acids by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. 2,4,6-Trimethylpyrylium tetrafluoroborate (TMPy), 2,4-diphenyl-pyranylium tetrafluoroborate (DPP-TFB), 4-(anthracen-9-yl)-2-fluoro-1-methylpyridin-1-ium iodide (FMP-10), and triphenyl pyrilium (TPP) were used as derivatization reagents that can specifically modify primary amines or hydroxy groups in target molecules. Three derivatization reagents, not including TPP, reacted with all target molecules. The derived catecholamines dopamine and L-DOPA, and the amino acids GABA and glycine, were efficiently ionized in comparison with non-derivatized targets. Comparative analysis indicated that TMPy and FMP-10 produced general increases in signal-to-noise ratios (S/N), whereas DPP and TPP produced specific increases in the S/N of GABA and DA. Notably, TMPy is a small molecule that efficiently reacts with target molecules due to the absence of high bulk and steric hinderance.
- Open Access
- 23 March 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-12
Structure based analysis of KATP channel with a DEND syndrome mutation in murine skeletal muscle
Developmental delay, epilepsy, and neonatal diabetes (DEND) syndrome, the most severe end of neonatal diabetes mellitus, is caused by mutation in the ATP-sensitive potassium (KATP) channel. In addition to diabetes, DEND patients present muscle weakness as one of the symptoms, and although the muscle weakness is considered to originate in the brain, the pathological effects of mutated KATP channels in skeletal muscle remain elusive. Here, we describe the local effects of the KATP channel on muscle by expressing the mutation present in the KATP channels of the DEND syndrome in the murine skeletal muscle cell line C2C12 in combination with computer simulation. The present study revealed that the DEND mutation can lead to a hyperpolarized state of the muscle cell membrane, and molecular dynamics simulations based on a recently reported high-resolution structure provide an explanation as to why the mutation reduces ATP sensitivity and reveal the changes in the local interactions between ATP molecules and the channel.
- 23 March 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-12
Open AccessStructure based analysis of KATP channel with a DEND syndrome mutation in murine skeletal muscle
Developmental delay, epilepsy, and neonatal diabetes (DEND) syndrome, the most severe end of neonatal diabetes mellitus, is caused by mutation in the ATP-sensitive potassium (KATP) channel. In addition to diabetes, DEND patients present muscle weakness as one of the symptoms, and although the muscle weakness is considered to originate in the brain, the pathological effects of mutated KATP channels in skeletal muscle remain elusive. Here, we describe the local effects of the KATP channel on muscle by expressing the mutation present in the KATP channels of the DEND syndrome in the murine skeletal muscle cell line C2C12 in combination with computer simulation. The present study revealed that the DEND mutation can lead to a hyperpolarized state of the muscle cell membrane, and molecular dynamics simulations based on a recently reported high-resolution structure provide an explanation as to why the mutation reduces ATP sensitivity and reveal the changes in the local interactions between ATP molecules and the channel.
- Open Access
- 24 December 2019
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 13 (1) , 1-6
Cluster of differentiation 8 and programmed cell death ligand 1 expression in triple-negative breast cancer combined with autosomal dominant polycystic kidney disease and tuberous sclerosis complex: a case report
Background: Autosomal dominant polycystic kidney disease is defined as an inherited disorder characterized by renal cyst formation due to mutations in the PKD1 or PKD2 gene, whereas tuberous sclerosis complex is an autosomal dominant neurocutaneous syndrome caused by mutation or deletion of the TSC2 gene. A TSC2/PKD1 contiguous gene syndrome, which is caused by a chromosomal mutation that disrupts both the TSC2 and PKD1 genes, has been identified in patients with tuberous sclerosis complex and severe early-onset autosomal dominant polycystic kidney disease. The tumor tissue of patients with breast cancer with contiguous gene syndrome has a high mutation burden and produces several neoantigens. A diffuse positive immunohistochemistry staining for cluster of differentiation 8+ in the T cells of breast cancer tissue is consistent with neoantigen production due to high mutation burden. Case presentation: A 61-year-old Japanese woman who had been undergoing dialysis for 23 years because of end-stage renal failure secondary to autosomal dominant polycystic kidney disease was diagnosed as having triple-negative breast cancer and underwent mastectomy in 2015. She had a history of epilepsy and skin hamartoma. Her grandmother, mother, two aunts, four cousins, and one brother were also on dialysis for autosomal dominant polycystic kidney disease. Her brother had epilepsy and a brain nodule. Another brother had a syndrome of kidney failure, intellectual disability, and diabetes mellitus, which seemed to be caused by mutation in the CREBBP gene. Immunohistochemistry of our patient’s breast tissue showed cluster of differentiation 8 and programmed cell death ligand 1 positivity. Conclusions: Programmed cell death ligand 1 checkpoint therapy may be effective for recurrence of triple-negative breast cancer in a patient with autosomal dominant polycystic kidney disease and tuberous sclerosis complex.
- 24 December 2019
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 13 (1) , 1-6
Open AccessCluster of differentiation 8 and programmed cell death ligand 1 expression in triple-negative breast cancer combined with autosomal dominant polycystic kidney disease and tuberous sclerosis complex: a case report
Background: Autosomal dominant polycystic kidney disease is defined as an inherited disorder characterized by renal cyst formation due to mutations in the PKD1 or PKD2 gene, whereas tuberous sclerosis complex is an autosomal dominant neurocutaneous syndrome caused by mutation or deletion of the TSC2 gene. A TSC2/PKD1 contiguous gene syndrome, which is caused by a chromosomal mutation that disrupts both the TSC2 and PKD1 genes, has been identified in patients with tuberous sclerosis complex and severe early-onset autosomal dominant polycystic kidney disease. The tumor tissue of patients with breast cancer with contiguous gene syndrome has a high mutation burden and produces several neoantigens. A diffuse positive immunohistochemistry staining for cluster of differentiation 8+ in the T cells of breast cancer tissue is consistent with neoantigen production due to high mutation burden. Case presentation: A 61-year-old Japanese woman who had been undergoing dialysis for 23 years because of end-stage renal failure secondary to autosomal dominant polycystic kidney disease was diagnosed as having triple-negative breast cancer and underwent mastectomy in 2015. She had a history of epilepsy and skin hamartoma. Her grandmother, mother, two aunts, four cousins, and one brother were also on dialysis for autosomal dominant polycystic kidney disease. Her brother had epilepsy and a brain nodule. Another brother had a syndrome of kidney failure, intellectual disability, and diabetes mellitus, which seemed to be caused by mutation in the CREBBP gene. Immunohistochemistry of our patient’s breast tissue showed cluster of differentiation 8 and programmed cell death ligand 1 positivity. Conclusions: Programmed cell death ligand 1 checkpoint therapy may be effective for recurrence of triple-negative breast cancer in a patient with autosomal dominant polycystic kidney disease and tuberous sclerosis complex.
- Open Access
- 28 October 2019
- Published by Springer Nature in BMC Research Notes
- Vol. 12 (1) , 1-4
Association between cognitive impairment patient with solid cancer and insulin resistance
Objectives: In an aging population, an increase in the number of elderly cancer patients with cognitive impairment is expected. The possible association between cancer and cognitive impairment is important to elucidate, because it can have a serious impact on quality of life. Here, we focused on glucose metabolism as a factor that links cancer and cognitive impairment. Results: Thirteen subjects with solid cancers and cognitive impairment were recruited. As a control group, 14 subjects with cognitive impairment alone and 8 subjects with cancer alone were recruited. A Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and that of β-cell function (HOMA-B) were used. In comparison with patients with solid cancer alone, those with cognitive impairment alone and those with both cancer and cognitive impairment had increased HOMA-IR values. Insulin resistance was increased in patients with cognitive impairment alone and those with both cognitive impairment and solid cancer than in patients without cognitive impairment; however, β-cell function was not affected. The present data indicated that elderly cancer patients with high HOMA-IR score may be at a relatively high risk for developing cognitive impairment. Furthermore, early treatment to reduce insulin sensitivity may prevent cognitive impairment.
- 28 October 2019
- Published by Springer Nature in BMC Research Notes
- Vol. 12 (1) , 1-4
Open AccessAssociation between cognitive impairment patient with solid cancer and insulin resistance
Objectives: In an aging population, an increase in the number of elderly cancer patients with cognitive impairment is expected. The possible association between cancer and cognitive impairment is important to elucidate, because it can have a serious impact on quality of life. Here, we focused on glucose metabolism as a factor that links cancer and cognitive impairment. Results: Thirteen subjects with solid cancers and cognitive impairment were recruited. As a control group, 14 subjects with cognitive impairment alone and 8 subjects with cancer alone were recruited. A Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and that of β-cell function (HOMA-B) were used. In comparison with patients with solid cancer alone, those with cognitive impairment alone and those with both cancer and cognitive impairment had increased HOMA-IR values. Insulin resistance was increased in patients with cognitive impairment alone and those with both cognitive impairment and solid cancer than in patients without cognitive impairment; however, β-cell function was not affected. The present data indicated that elderly cancer patients with high HOMA-IR score may be at a relatively high risk for developing cognitive impairment. Furthermore, early treatment to reduce insulin sensitivity may prevent cognitive impairment.
- Open Access
- 2 May 2019
- Published by Springer Nature in BMC Medical Genetics
- Vol. 20 (1) , 67
MLH1 germline mutation associated with Lynch syndrome in a family followed for more than 45 years
Lynch syndrome, is an autosomal dominantly inherited disease that predisposes individuals to a high risk of colorectal cancers, and some mismatch-repair genes have been identified as causative genes. The purpose of this study was to investigate the genomic rearrangement of the gene in a family with Lynch syndrome followed for more than 45 years. The family with Lynch syndrome is family N, who received colorectal cancer treatment for 45 years. The proband of family N had multiple colorectal and uterine cancers. Because the proband met the diagnostic Amsterdam criteria and was Microsatellite instability (MSI) - positive, we performed genetic testing several times. However, germline mutations in MLH1 and MSH2 genes were not found by long-distance PCR or RT-PCR/direct sequencing analysis within the 45-year follow-up. MLPA analysis showed that the genomes of the proband and proband’s daughter contained a deletion from exon 4 through exon 19 in the MLH1 gene. Her son’s son and her daughter’s son were found to be carriers of the mutation. For carriers of mismatch-repair gene mutation among families with Lynch syndrome, the onset risk of associated cancers such as uterine cancer is particularly high, including colorectal cancer. The diagnosis of carriers among non-onset relatives is important for disease surveillance.
- 2 May 2019
- Published by Springer Nature in BMC Medical Genetics
- Vol. 20 (1) , 67
Open AccessMLH1 germline mutation associated with Lynch syndrome in a family followed for more than 45 years
Lynch syndrome, is an autosomal dominantly inherited disease that predisposes individuals to a high risk of colorectal cancers, and some mismatch-repair genes have been identified as causative genes. The purpose of this study was to investigate the genomic rearrangement of the gene in a family with Lynch syndrome followed for more than 45 years. The family with Lynch syndrome is family N, who received colorectal cancer treatment for 45 years. The proband of family N had multiple colorectal and uterine cancers. Because the proband met the diagnostic Amsterdam criteria and was Microsatellite instability (MSI) - positive, we performed genetic testing several times. However, germline mutations in MLH1 and MSH2 genes were not found by long-distance PCR or RT-PCR/direct sequencing analysis within the 45-year follow-up. MLPA analysis showed that the genomes of the proband and proband’s daughter contained a deletion from exon 4 through exon 19 in the MLH1 gene. Her son’s son and her daughter’s son were found to be carriers of the mutation. For carriers of mismatch-repair gene mutation among families with Lynch syndrome, the onset risk of associated cancers such as uterine cancer is particularly high, including colorectal cancer. The diagnosis of carriers among non-onset relatives is important for disease surveillance.